Angiopoietin-like 4 (Angptl4) Protein Is a Physiological Mediator of Intracellular Lipolysis in Murine Adipocytes
Department of Nutritional Science and Toxicology, University of California, Berkeley, California 94720-3104, USA. Journal of Biological Chemistry
(Impact Factor: 4.57).
01/2012; 287(11):8444-56. DOI: 10.1074/jbc.M111.294124
Intracellular triacylglycerol (TG) hydrolysis and fatty acid release by the white adipose tissue (WAT) during a fast is stimulated by counter-regulatory factors acting in concert, although how adipocytes integrate these lipolytic inputs is unknown. We tested the role of angiopoietin-like 4 (Angptl4), a secreted protein induced by fasting or glucocorticoid treatment, in modulating intracellular adipocyte lipolysis. Glucocorticoid receptor blockade prevented fasting-induced tissue Angptl4 expression and WAT TG hydrolysis in mice, and TG hydrolysis induced by fasts of 6 or 24 h was greatly reduced in mice lacking Angptl4 (Angptl4(-/-)). Glucocorticoid treatment mimicked the lipolytic effects of fasting, although with slower kinetics, and this too required Angptl4. Thus, fasting-induced WAT TG hydrolysis requires glucocorticoid action and Angptl4. Both fasting and glucocorticoid treatment also increased WAT cAMP levels and downstream phosphorylation of lipolytic enzymes. Angptl4 deficiency markedly reduced these effects, suggesting that Angptl4 may stimulate lipolysis by modulating cAMP-dependent signaling. In support of this, cAMP levels and TG hydrolysis were reduced in primary Angptl4(-/-) murine adipocytes treated with catecholamines, which stimulate cAMP-dependent signaling to promote lipolysis, and was restored by treatment with purified human ANGPTL4. Remarkably, human ANGPTL4 treatment alone increased cAMP levels and induced lipolysis in these cells. Pharmacologic agents revealed that Angptl4 modulation of cAMP-dependent signaling occurs upstream of adenylate cyclase and downstream of receptor activation. We show that Angptl4 is a glucocorticoid-responsive mediator of fasting-induced intracellular lipolysis and stimulates cAMP signaling in adipocytes. Such a role is relevant to diseases of aberrant lipolysis, such as insulin resistance.
Available from: Gerald Rimbach
- "mRNA expression in WAT in APOE4 TR mice may moreover lead to the delayed VLDL clearance that has been reported before . Interestingly, non-esterified fatty acids (NEFA) are stimulators of ANGPTL4 expression  and ANGPTL4 triggers lipolysis of stored triglycerides in adipocytes  and thus secretion of fasting NEFA. Therefore the higher fasting plasma NEFA in our APOE4 mice are indicative of increased fatty acid mobilization from WAT via hormone-sensitive lipase (HSL) and simultaneously trigger lipolytic activity via Angptl4 induction (Figure 4). "
[Show abstract] [Hide abstract]
ABSTRACT: ScopeOf the three human apolipoprotein E (APOE) alleles, the ε3 allele is most common, which may be a result of adaptive evolution. In this study, we investigated whether the APOE genotype affects body weight and energy metabolism through regulation of fatty acid utilization.Methods and resultsTargeted replacement mice expressing the human APOE3 were significantly heavier on low- and high-fat diets compared to APOE4 mice. Particularly on high-fat feeding, food intake and dietary energy yields as well as fat mass were increased in APOE3 mice. Fatty acid mobilization determined as activation of adipose tissue lipase and fasting plasma nonesterified fatty acid levels were significantly lower in APOE3 than APOE4 mice. APOE4 mice, in contrast, exhibited higher expression of proteins involved in fatty acid oxidation in skeletal muscle.Conclusion
Our data suggest that APOE3 is associated with the potential to more efficiently harvest dietary energy and to deposit fat in adipose tissue, while APOE4 carriers tend to increase fatty acid mobilization and utilization as fuel substrates especially under high-fat intake. The different handling of dietary energy may have contributed to the evolution and worldwide distribution of the ε3 allele.
Available from: Rucha Patel
- "The authors showed that Angptl4 is a direct target of GR using both ChIP and promoter reporter studies (102). Subsequent studies by Gray et al (2012) showed that 24 hrs of fasting induced Angptl4 expression in the liver and white adipose tissues in a GR dependent manner (the effect was attenuated by RU-486 treatment) (101). In addition, lipolysis induced by fasting or Dex-treatment was severely impaired in WAT from Angptl4-/-mice (101). "
[Show abstract] [Hide abstract]
ABSTRACT: The glucocorticoid receptor was one of the first nuclear hormone receptors cloned and represents one of the most effective drug targets available today for the treatment of severe inflammation. The physiologic consequences of endogenous or exogenous glucocorticoid excess are well established and include hyperglycemia, insulin resistance, fatty liver, obesity and muscle wasting. However, at the molecular and tissue-specific level, there are still many unknown protein mediators of glucocorticoid response and thus, much remains to be uncovered that will help determine whether activation of the glucocorticoid receptor can be tailored to improve therapeutic efficacy while minimizing unwanted side effects. This review summarizes recent discoveries of tissue-selective modulators of glucocorticoid signaling that are important in mediating the unwanted side effects of therapeutic glucocorticoid use, emphasizing the downstream molecular effects of GR activation in the liver, adipose tissue, muscle and pancreas.
Available from: sciencedirect.com
- "Alternatively, Angptl4 may affect intracellular lipolysis of fat stores in adipose tissue. Gray et al. showed that Angptl4 À /À mice had decreased glycerol release of fat pad explants and decreased plasma FFA levels when fasted . Accordingly, decreased lipolysis in adipocytes lacking Angptl4 may result in enhanced lipid accumulation. "
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.